Document Detail

Prior antiretroviral therapy experience protects against zidovudine-related anaemia.
MedLine Citation:
PMID:  17760739     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: We investigated the use of antiretroviral therapy regimens containing zidovudine or stavudine, using data from the TREAT Asia HIV Observational Database (TAHOD), a multicentre, prospective, observational study of an HIV-infected cohort in the Asia-Pacific Region. METHODS: A proportional hazards regression analysis of factors associated with the time to discontinuation of initial regimens containing zidovudine or stavudine and a logistic regression analysis to identify factors associated with a diagnosis of anaemia within 6 months of commencement of zidovudine in initial or subsequent regimens were performed. RESULTS: Patients who started zidovudine were more likely to stop within the first 9 months of treatment than those who started on stavudine; the reverse was true after 9 months. Anaemia (haemoglobin<or=10 g/dL) occurred in the first 6 months in 57 of 433 patients (13%) on zidovudine. Baseline anaemia was the strongest predictive factor for subsequent anaemia, and prior antiretroviral therapy (ART) experience was protective for development of anaemia. CONCLUSIONS: These data support baseline haemoglobin testing and avoidance of zidovudine if the patient is anaemic. The protective effect of prior ART for development of anaemia on zidovudine supports the short-term safety of a stavudine to zidovudine switch with routine haemoglobin monitoring in this cohort. Further studies in resource-poor settings of longer term efficacy and toxicities of ART switch strategies are needed.
S E Huffam; P Srasuebkul; J Zhou; A Calmy; V Saphonn; J M Kaldor; R Ditangco;
Related Documents :
15980689 - Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combi...
16279899 - Response of hepatitis c genotype-4 naïve patients to 24 weeks of peg-interferon-alpha2...
20558919 - Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded ...
9310219 - Physician concurrence with primary care guidelines for persons with hiv disease.
21834769 - Novel design and synthesis of modified structure of carvedilol.
16764659 - Biologic therapies for inflammatory eye disease.
21939609 - An electronic clinic for arthroplasty follow-up: a pilot study.
17413629 - Use of the diode laser with intraoperative mitomycin c in endocanalicular laser dacryoc...
23983149 - Repeat post-op voiding trials: an inconvenient correlate with success.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  HIV medicine     Volume:  8     ISSN:  1464-2662     ISO Abbreviation:  HIV Med.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-08-31     Completed Date:  2008-03-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897392     Medline TA:  HIV Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  465-71     Citation Subset:  IM    
National Center for HIV/AIDS, Dermatology and STDs (NCHADS), Ministry of Health, Phnom Penh, Cambodia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acquired Immunodeficiency Syndrome / drug therapy*
Anemia / chemically induced,  prevention & control*
Anti-HIV Agents / adverse effects*
Antiretroviral Therapy, Highly Active / methods*
Developing Countries
Drug Therapy, Combination
HIV / drug effects
HIV Infections / drug therapy*
Middle Aged
Multivariate Analysis
Retrospective Studies
Zidovudine / adverse effects*
Grant Support
Reg. No./Substance:
0/Anti-HIV Agents; 30516-87-1/Zidovudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone a...
Next Document:  Risk factors for death among patients in French Guiana: 1996-2005.